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Abstract
Background: Type 4 phosphodiesterase (PDE4) inhibitors have been shown to stimulate bone
formation in vivo and to stimulate osteoblastic differentiation in vitro. As one possible mechanism
for the stimulation of bone formation is the recruitment of osteoprogenitor cells from the bone
marrow, we have investigated the effect of the PDE4 inhibitors EMD273316, EMD95833,
EMD249615 and EMD 219906 on fibroblastic colony formation by whole bone marrow cells and
on the ability of these colonies to adopt an osteoblastic phenotype.
Results: All four agents stimulated colony formation in a concentration dependent manner,
however, in the case of EMD273316 & EMD95833, the effect was evident at lower concentrations
and the addition of prostaglandin E2 (PGE2) was not necessary for maximal stimulation. It was
subsequently found that co-incubation with indomethacin reduced the stimulatory effects of
EMD273316 & EMD95833 but had no effect on the actions of EMD249615 and EMD 219906 and
that EMD273316 & EMD95833 stimulated the synthesis of endogenous PGE2 by whole bone
marrow cells whereas EMD249615 and EMD 219906 had no significant effect.
Conclusions: These data suggest that EMD249615, EMD 219906, EMD273316 & EMD95833 can
promote the recruitment of bone marrow osteoprogenitor cells leading to a stimulation of bone
formation via their direct inhibitory effects on PDE4. The actions of EMD273316 & EMD95833
however, are augmented by their ability to stimulate endogenous prostanoids synthesis which acts
synergistically with their direct effects on PDE4.
Background
Most bone anabolic agents such as prostaglandin E2
(PGE2), 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) and
parathyroid hormone (PTH) have receptors that are dis-
tributed widely throughout the body and in multiple tis-
sue types. Because of this broad receptor distribution,
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prevent their widespread use, and it is likely that the
development of specific bone agonists will prove
extremely difficult. An alternative strategy would be to
develop compounds which tissue-selectively potentiate
the actions of endogenous agents at the cellular level.
Such compounds may act either directly on the agents
themselves or on the downstream products of their
respective signaling pathways. For example, PTH and
PGE2 both act via a receptor mediated mechanism that
raises intracellular levels of cyclic AMP, thereby stimulat-
ing a range of cyclic nucleotide-dependent kinases. Under
normal physiological conditions, cyclic AMP is rapidly
degraded by a family of enzymes known as cyclic nucle-
otide phosphodiesterases (PDE). By preventing this deg-
radation, PDE inhibitors may provide a useful strategy for
potentiating the actions of endogenous PTH and PGE2 by
both amplifying and prolonging the cyclic AMP response
to these agents.
Consistent with this possibility, PDEs, which can be clas-
sified into at least 11 genetically distinct families (PDE1-
11), show differential tissue distribution and PDE inhibi-
tors have been generated which possess tissue selectivity
[1,2]. Subsequently, specific PDE inhibitors have been
successfully developed as tissue-selective treatments in
other therapeutic areas, such as sildenafil in erectile dys-
function. PDE4 inhibitors appear to stimulate bone for-
mation in vitro and in vivo and have been suggested as
possible antiosteoporotic drugs [3]. For example, several
PDE4 inhibitors have been shown to stimulate the recruit-
ment of osteoprogenitors from bone marrow in vitro
including rolipram, EMD 95833, XT-44 and denbufylline
[4-7]. This activity has subsequently been confirmed in a
number of animal models including sarcoma-bearing rats
[6,7] denervated rats [6] and normal mice [8]. Although
PDE inhibitors were originally thought to stimulate bone
formation by potentiation of PGE2 and PTH, other regula-
tory factors also appear to be involved, in light of the
recent finding that pentoxifylline and rolipram both
potentiate the induction of osteogenesis by BMP-2 [9,10].
In this study we have investigated the ability of a series of
PDE4 inhibitors to stimulate the recruitment of osteopro-
genitors present in bone marrow as determined by the
fibroblastic colony forming unit assay. We find that in
addition to their PDE4-inhibitory activity, 2 of the com-
pounds could also stimulate PGE2 synthesis which syner-
gized with the original activity.
Results
Initial experiments using the non-selective PDE inhibitor,
isobutylmethylxanthine (IBMX) and the PDE4 inhibitor
rolipram, showed that treatment with these agents alone
could give rise to a significant stimulation in colony
number. However, it was also found that co-treatment
with concentrations of PGE2 as low as 0.1 nM, which do
not normally have any effect in this system, produced
almost maximal responses which were of similar magni-
tude to treatment with 100 nM PGE2 alone (fig. 1a &1b).
A number of recently developed PDE4 inhibitors (Merck
KGaA, Darmstadt, Germany) having broadly similar activ-
ities with respect to PDE4 inhibition whilst being consid-
erably less active in terms of PDE3 inhibition (table 1)
were screened for their ability to stimulate colony forma-
tion in the CFU-f assay. It was found that these varied
greatly in their potency with EMD273316 and EMD95833
both producing significant responses at 1 nM and having
a maximal effect at 1 µM. In contrast, neither EMD249615
nor EMD219906 produced a significant response at con-
centrations lower than 1 µM (Fig. 2). It was also found
that, parallel to the increase in total colony number, there
was a general increase in the number of colonies display-
ing characteristics typical of an osteoblastic phenotype,
i.e. alkaline phosphatase expression and calcium deposi-
tion (fig. 3). The proportion of alkaline phosphatase and
calcium positive colonies remains fairly constant through-
out with no significant difference being found between
controls and cultures treated with PDE-inhibitors.
Furthermore, it was found that in contrast to IBMX and
rolipram, the addition of exogenous PGE2 had no consist-
ent additional effect on the actions of EMD273316 and
EMD95833 (fig. 4). This would suggest that at least a part
of the action of these agents is mediate via the induction
of endogenous prostanoid synthesis. To test this hypothe-
sis, cells were exposed to the PDE4 inhibitors EMD95833,
EMD273316, EMD219906 or EMD249615 at a concen-
tration of 1 µM (the optimal concentration for all 4
agents) in the presence or absence of the cyclooxygenase
inhibitor indomethacin (3 µM). This resulted in a signifi-
cant decrease in the response to the 2 most active PDE
inhibitors, EMD95833 and EMD273316. Co-treatment
with 3 µM indomethacin also resulted in a decrease in the
effects of the less active agents, EMD219906 and
EMD249615, however, this did not achieve statistical sig-
nificance (fig. 5a). Analysis of the cell culture medium
from the experiment described in fig. 5a revealed that
both EMD95833 and EMD273316 caused a significant
increase in PGE2 synthesis which was abrogated by co-
treatment with 3 µM indomethacin. In contrast neither
EMD219906 nor EMD249615 had any significant effect
on prostaglandin levels (fig. 5b).
Conclusions
In this investigation we have shown that a number of
PDE4 inhibitors, including rolipram, IBMX, EMD219906,
EMD249615, EMD273316 & EMD95833, stimulate col-
ony formation by rat bone marrow cells in the CFU-fPage 2 of 9
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alkaline phosphatase and depositing a calcified matrix,
both markers associated with osteogenesis, increased pro-
portionately. In the past we have suggested that positive
activity in the CFU-f assay may have some value as a pre-
dictor of bone anabolic activity in vivo. This is because a
number of agents known to stimulate bone formation in
vivo such as PGE2 [11,12] or FGF-2 [13,14] have also been
found to be potent stimulators of colony formation in the
CFU-f assay [15-17]. These data therefore, suggest that the
increased bone formation seen in animals treated with
various PDE4 inhibitors [6-8] may be mediated by the
induction of recruitment and differentiation of bone mar-
row stromal cells.
These data are broadly in agreement with other reports on
the effects of PDE4 inhibitors on osteoprogenitor cells.
XT-44, Ro 20-1724 and denbufylline have all been shown
to increase mineralised nodule formation in primary cul-
tures of rat bone marrow cells [6,7] and pentoxifylline and
rolipram stimulated the expression of alkaline phos-
phatase in the bone marrow stromal cell line, ST2 [4,18].
The experiments described in these investigations all used
monolayer cultures of either cell lines or primary bone
Synergistic interaction between (a). IBMX or (b). rolipram and PGE2 on fibroblastic colony formation by whole bone marrowFigu e 1
Synergistic interaction between (a). IBMX or (b). rolipram and PGE2 on fibroblastic colony formation by whole bone marrow. 
Whole bone marrow was prepared and cultured in the CFU-f assay as described in the text in the presence of either (a). 10 
µM IBMX or (b). 10 µM rolipram in combination with varying concentrations of PGE2. The medium was changed for fresh, PDE 
inhibitor & PGE2-free, medium after 5 d and thereafter twice weekly. The cultures were then stopped after 18 d, fixed with 
cold ethanol and stained for total colonies with methylene blue. They were then photographed and quantitated. Data pre-
sented are mean colony numbers per Petri dish ± S.D. * Denotes significant difference from control cultures, p < 0.05; # 
denotes significant difference from corresponding IBMX or rolipram-free cultures, p < 0.05.
Table 1: Effect of the PDE inhibitors on the activity of PDE3 and PDE4. Data are presented as means ± S.E.M except in the case PDE3 
where a satisfactory IC50 for 3 of the compounds could not be calculated.
PDE inhibitor PDE3 PDE4
EMD95833 33% inhibition at 3 µM IC50 = 0.1 ± 0.004 µM
EMD219906 IC50 = 1.3 ± 0.06 µM IC50 = 0.48 ± 0.03 µM
EMD249615 39% inhibition at 3 µM IC50 = 0.074 ± 0.004 µM
EMD273316 46% inhibition at 3 µM IC50 = 0.33 ± 0.01 µM
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take place, as shown by the results using cell lines, under
these conditions it is not possible to say whether the
increase in the numbers of mineralised nodules could be
due to increases in the numbers of cells differentiating or
due to the proliferation or recruitment of osteoprogenitor
cells. In this study however, we have used CFU-f cultures
which measure the numbers of proliferating stromal cells
present in whole bone marrow. The increase in colony
numbers seen after treatment with the PDE inhibitors,
suggests that stromal cells, that would otherwise have
remained quiescent, have been activated and induced to
proliferate. As the proportion of colonies expressing alka-
line phosphatase remained fairly constant throughout, it
seems likely that the increase differentiation is due to an
increase in the recruitment of precursor cells rather than a
direct effect on differentiation.
The principle action of these drugs is to inhibit the
enzyme Type 4 phosphodiesterase and thereby increase
intracellular levels of cyclic AMP. It might therefore, be
expected that they would only be active in the presence of
agents such as PTH or PGE2, that act by stimulating the
synthesis of cyclic AMP. Indeed a number of the agents
Effect of PDE4 inhibitors on fibroblastic colony formation by whole bone marrowFigure 2
Effect of PDE4 inhibitors on fibroblastic colony formation by whole bone marrow. Whole bone marrow was prepared and cul-
tured in the CFU-f assay as described in the text and treated with varying concentrations of the PDE4 inhibitors EMD 273316, 
EMD95833, EMD249615 or EMD219906. Medium changes, fixation and staining were as in Fig. 1. 10-7 M PGE2 was used as a 
positive control in these experiments. Data presented are mean colony numbers per Petri dish ± S.D. * Denotes significant dif-
ference from control cultures, p < 0.05.
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EMD249615 produced only modest effects when used in
isolation. However, when used in combination with
PGE2, synergistic effects were seen such that almost maxi-
mal stimulation of colony number was achieved at
concentrations of PGE2 that do not normally have a signif-
icant effect in this system. The mechanism underlying the
stimulation seen in response to these agents in the
absence of exogenous prostanoids is open to speculation.
It is possible that non-prostanoid agents present in the
cultures are responsible for a basal level of cyclic AMP syn-
thesis or alternatively, low levels of prostanoids, below
the detection limit of the ELISA used, may be responsible.
In contrast EMD95833 and EMD273316 gave rise to sig-
nificant increases in colony number in the absence of
Effect of the PDE4 inhibitor EMD95833 on fibroblastic colony formation and osteoblastic differentiationFigure 3
Effect of the PDE4 inhibitor EMD95833 on fibroblastic colony formation and osteoblastic differentiation. Whole bone marrow 
was prepared and cultured in the CFU-f assay as described in the text and treated with varying concentrations of EMD95833. 
In order to assess the effects of EMD95833 on osteoblastic differentiation, after fixation the cells were stained for alkaline 
phosphatase with naphtholphosphate/fast red, calcium deposition with alizarin red and total colonies with methylene blue. Data 
presented are mean colony numbers per Petri dish ± S.D. * Denotes significant difference from the appropriately stained con-
trol cultures, p < 0.05.
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suggests that these agents stimulate the production of
endogenous stimulators of cyclic AMP synthesis such as
prostanoids. To support this hypothesis, inhibition of
prostanoid synthesis by the addition of indomethacin to
the cultures abrogated the stimulatory effects of the PDE
inhibitors. Furthermore, direct measurement of PGE2 in
the culture medium revealed that both EMD273316 and
EMD95833 stimulated the production of PGE2 by whole
bone marrow cells whereas EMD219906 and
EMD249615 had no such effect. This is consistent with
the effects of PDE4 inhibitors in other systems. PGE2 pro-
duction has been shown to be stimulated by a number of
specific PDE4 inhibitors in various cell types including
bovine airway smooth muscle cells by Ro-20-1724 [19],
whole blood by RP73401 [20] and human peripheral
blood mononuclear cells by rolipram and CDP840 [21].
It is known that prostaglandins are derived from arachi-
donic acid via the actions of two enzymes termed cycloox-
ygenase-1 (COX-1) and cylooxygenase-2 (COX-2).
Broadly speaking COX-1 is thought to be present at
relatively constant levels and is responsible for the house-
keeping functions of prostanoids. In contrast, COX-2
expression is induced by a wide variety of cytokines,
growth factors and other stimuli and is involved in the
acute response to a number of pathological situations, in
particular inflammation [22]. The fact that PGE2 synthesis
was increased after the addition of EMD273316 and
EMD95833 would suggest the involvement of COX-2
however, this will need to be confirmed using specific
Interaction between PDE4 inhibitors and PGE2Figure 4
Interaction between PDE4 inhibitors and PGE2. CFU-f cultures were carried out as described in Fig. 1 and the cells treated 
with 1 µM EMD273316, EMD95833, EMD249615 or EMD219906 in the presence or absence of 1 nM PGE2. Data presented 
are mean colony numbers per Petri dish ± S.D. * Denotes significant difference from control cultures, p < 0.05; # denotes sig-
nificant difference from corresponding PGE2-free cultures, p < 0.05.
Treatment
cont
rol
1nm
PGE
2
EMD
2733
16
EMD
2199
06
EMD
2496
15
EMD
9583
3
C
ol
on
ie
s 
pe
r 
di
sh
0
50
100
150
200
250
300
PDEI alone
PDEI + 1nM PGE2
*
*#
*#*
* *
*
*Page 6 of 9
(page number not for citation purposes)
BMC Pharmacology 2004, 4 http://www.biomedcentral.com/1471-2210/4/10inhibitors. Recently, Miyamoto et al [23] demonstrated
that the PDE4 inhibitor XT-611 also gave rise to bone-ana-
bolic effects in an in vitro bone marrow culture system.
The system used was slightly different to that described
above in that determined calcified nodule formation in
confluent cultures of bone marrow cells. However, they
did show that XT-611 stimulated PGE2 accumulation
which potentiated the PDE4-related actions of XT-611.
Furthermore they showed that this effect could be blocked
by the addition of the COX-2 antagonists zaltoprofen and
NS-398 [23].
In summary, these data suggest that the bone anabolic
effects of PDE4 inhibitors may be mediated by the recruit-
ment and proliferation of quiescent bone marrow stromal
cells followed by their osteoblastic differentiation. In the
case of EMD219906 and EMD249615 this effect appears
to be due to their direct effects on PDE4. EMD273316 and
EMD95833 however, also stimulate the synthesis of
endogenous PGE2 synthesis which then synergises with
the PDE inhibitors enabling them to achieve maximal
stimulation in the absence of exogenous stimulators of
cyclic AMP synthesis.
Methods
Materials
EMD95833, EMD273316, EMD219906 and EMD249615
were supplied by Merck KGaA, Darmstadt, Germany and
used as supplied. Stock solutions were prepared in DMSO
and then diluted in cell culture medium such that the final
concentration of DMSO in the medium was less than
0.1% v/v. Cell culture medium, Glutamax, and Penicillin-
Streptomycin and all other chemicals and reagents were
from Sigma Chemical Company Ltd. (Poole, Dorset,
U.K.). Serum supreme (modified newborn calf serum, SS)
was from Biowhittaker (Wokingham, UK). Tissue culture
plastics were obtained from Scientific Laboratory Supplies
(Nottingham, UK). Male Wistar rats (~200 g) were
obtained from Harlan (Bicester, UK) and kept according
to Home Office guidelines at the Sheffield University
Medical School animal facility.
Preparation of bone marrow cells
Pooled bone marrow cells (BMC) were obtained from tib-
ias and femurs from male Wistar rats. The bones were har-
vested under aseptic conditions, all soft tissue removed
and the BMC then harvested by the method of Dobson et
al [24]. Briefly, the proximal ends of the femurs and the
distal ends of the tibias were removed, a hole made in the
opposing ends of the bones with an 18 gauge syringe nee-
dle and the cells removed by centrifugation at 450 g for 1
min. The cells were then suspended in 10 ml Dulbecco's
modified Eagle's medium (DMEM) containing 10%
Serum Supreme (SS), 10-8 M dexamethasone and 50 µg/
ml ascorbic acid. The cells were then dispersed by repeated
pipetting, and a single cell suspension was achieved by
The role of endogenous prostanoid synthesis in PDE4 inhibitor-mediated stimulation of colony formationFigu e 5
The role of endogenous prostanoid synthesis in PDE4 inhibitor-mediated stimulation of colony formation. To test the hypoth-
esis that some of the PDE4 inhibitors were also acting via the stimulation of endogenous prostanoids synthesis, CFU-f cultures 
were challenged with either EMD95833, EMD273316, EMD219906 or EMD249615 (1 µM) in the presence or absence of 3 µM 
indomethacin (a.). Medium changes, fixation and staining were as in Fig. 1. In addition, immediately before the first medium 
change, 1 ml aliquots of medium from were removed and PGE2 levels determined by ELISA (b.). Data presented are means ± 
S.D. * Denotes significant difference from control cultures, p < 0.05, # denotes significant difference from corresponding 
indomethacin-free cultures, p < 0.05.
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needle. These cells were used in the CFU-f cultures as
follows:
Fibroblastic-colony forming units
In order to analyse CFU-f numbers, 2 × 106 BMC were
plated out in 55 cm2 petri dishes in DMEM containing
10% SS, 10-8 M dexamethasone and 50 µg/ml ascorbic
acid, together with vehicle, PDE inhibitor or PGE2 (10-7
M). The medium was changed after 5 days for DMEM con-
taining 10% FCS, 10-8 M dexamethasone and 50 µg/ml
ascorbic acid, and thereafter twice weekly. The cultures
were exposed to the agents for the first 5 days of the
culture period as previous experiments had shown that
this level of exposure achieved a maximal effect on colony
number. The cultures were maintained for 18 days after
which time the cells were washed with PBS and fixed by
the addition of cold ethanol. After fixation, the cultures
were stained sequentially for alkaline phosphatase
(APase), calcium and collagen positive colonies, and total
colonies as described below. After each staining proce-
dure, the culture dishes were photographed using a digital
camera and then destained. The images were analysed
using Bioimage "Intelligent Quantifier" and the number
of colonies was calculated.
Analyses
Alkaline phosphatase
After fixation with ethanol, the cultures were was stained
histochemically for APase as described by Bancroft and
Stevens [25]. The cells were exposed for 30 min at 20°C to
a solution of naphtholphosphate (0.05 mg/ml) in Tris
buffer (0.08 M, pH 7.5) containing fast red bb (1 mg/ml).
The cultures were then washed under running tap water,
photographed and then destained with absolute ethanol.
Calcium
Calcified colonies were identified by staining with alizarin
red pH 6.2 for 30 min followed by washing under running
tap water to remove unbound dye. The cultures were then
photographed and destained with 5% perchloric acid.
Total colony numbers
To assess total colony numbers, the cultures were stained
with 0.1% methylene blue in borate buffer (10 mM, pH
8.8) for 30 min, and then thoroughly washed under run-
ning tap water. The cultures were then photographed, and
the methylene blue positive CFU-f used as a measure of
total colony numbers.
Colony analysis
Colony numbers were assessed using the method of Dob-
son et al [26]. Briefly, the acquired digital images were
imported into Photoshop, colony irregularities smoothed
out and converted into a 256 level greyscale format. The
greyscale images were then imported into Bioimage
"Intelligent Quantifier" and the colony number
calculated.
Prostaglandin E2 determination
Before the first medium change on day 5, 1 ml aliquots of
medium were removed and PGE2 levels were determined
using a commercially available ELISA kit (Amersham)
according to the manufacturer's instructions.
Data handling and statistical analyses
Data are presented as group mean ± standard deviation. At
least 3 replicates of each experiment were performed, and
the results presented in the figures and tables of the report
are representative of these. For each variable, effects across
treatment groups were compared with one-way analysis of
variance (ANOVA). If the overall difference was signifi-
cant, multiple comparisons were performed between
groups with Tukey's test. Differences are considered signif-
icant at a probability <0.05 on a two-tailed test.
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